The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Abaloparatide Appears Safe, Effective for Boosting BMD in Women 80 & Up

Abaloparatide Appears Safe, Effective for Boosting BMD in Women 80 & Up

March 30, 2018 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Abaloparatide appears to be a safe and effective drug for increasing bone mineral density (BMD) in women 80 and older, new research shows.

You Might Also Like
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Abaloparatide Effective for Osteoporosis & XmAb5871 Studied to Treat SLE
  • BMD Not a Reliable Predictor of Vertebral Fragility Fracture in Older Women

The study is a post hoc analysis of the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, which found patients who received abaloparatide subcutaneously for 18 months had increased BMD and a lower risk of fractures compared with those on placebo.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Given “controversy” about the effectiveness and safety of treatments in the oldest old, Dr. Gary Hattersley of Radius Health, Inc. and colleagues performed a subgroup analysis in study participants 80 and older. Radius Health, which makes abaloparatide, funded the study.

There were 51 women 80 or older on abaloparatide, and 43 on placebo. Mean age was about 82 for both groups. Patients on active treatment had a 3.9% increase in total hip BMD, a 3.6% increase at the femoral neck and a 12.1% increase at the lumbar spine compared with those on placebo, similar to the effects seen in study participants at large.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The oldest women also had a numerical decline in vertebral and nonvertebral fractures compared to placebo that was similar to the overall ACTIVE group. “Tolerability and safety were also similar in the very elderly cohort versus the entire ACTIVE cohort,” the researchers write in Menopause, online February 16.

They conclude: “These findings are consistent with efficacy of abaloparatide in the very elderly comparable to that of the general older population.”

Dr. Hattersley was not available for an interview by press time.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. McClung MR, Harvey NC, Fitzpatrick LA, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal womenaged 80 years or older with osteoporosis. Menopause. 2018 Feb 16. [Epub ahead of print]

Filed Under: Drug Updates Tagged With: abaloparatide, Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, bone mineral density (BMD), boosting BMD

You Might Also Like:
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Abaloparatide Effective for Osteoporosis & XmAb5871 Studied to Treat SLE
  • BMD Not a Reliable Predictor of Vertebral Fragility Fracture in Older Women
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.